Cardiovascular Metabolic Risk Factor Mechanisms

The Randle cycle governs substrate competition in the heart. Chronic FAO dominance in obesity/insulin resistance reduces metabolic flexibility and drives cardiac dysfunction.

SGLT2i reduce HF hospitalization and CV death across the EF spectrum. The initial ketone hypothesis has given way to myocardial metabolic reprogramming, AMPK-sirtuin-autophagy activation, and NHE1 inhibition as leading candidates.

Semaglutide reduces CV mortality in non-diabetic obese patients independent of weight loss. Molecular cascades include AMPK/NO-mediated mitochondrial efficiency, calcium handling improvements, and GLP-1R-independent actions.

Both GIPR agonism and antagonism decrease body weight via distinct CNS mechanisms. Continuous stimulation may paradoxically desensitize the receptor. The full mechanistic contribution remains one of the most puzzling questions in CV pharmacology.

HFpEF is characterized by nutrient excess and lipotoxicity; HFrEF by energy starvation and catabolic remodeling. This divergence has direct implications for metabolic targeting of therapies.

All apoB-containing lipoproteins are causally atherogenic. TG-rich lipoproteins drive foam cell formation via intimal lipolysis. Lp(a) pathobiology involves oxidized phospholipid transport and monocyte activation. Novel RNA-targeting agents are in late-stage trials.

PCSK9 inhibition post-AMI is cardioprotective (reduced infarct size, inflammation, fibrosis). But PCSK9 deficiency may rewire cardiac metabolism toward an HFpEF-like phenotype — creating a complex risk-benefit picture.

T2D confers 35% higher AF risk and 2-4x increase in sudden cardiac arrest — independent of baseline CV risk. Mechanisms include ion channel remodeling, calcium dysregulation, epicardial adipose tissue invasion, and elevated BCAAs detectable years before T2D onset.

Metformin and GLP-2 reduce ischemia-reperfusion injury via gut microbiota modulation. Inter-organ signaling through cardiomyokines, hepatokines, adipokines, and gut metabolites is being decoded through multi-omics approaches.

Key unknowns include the directionality of inter-organ crosstalk, early biomarkers of multi-organ dysfunction, effects of isolated dyslipidemia on the heart, reversibility of shared pathogenic mechanisms, and sex/age-specific differences.